{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:41:13Z","timestamp":1760546473683},"reference-count":14,"publisher":"Akademiai Kiado Zrt.","issue":"34","license":[{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2023,8,27]]},"abstract":"<jats:p><jats:italic>Bevezet\u00e9s:<\/jats:italic> Az eur\u00f3pai \u00e9s a hazai hypertoniaaj\u00e1nl\u00e1sokban kiemelt\n                    helyen szerepelnek a k\u00fcl\u00f6nb\u00f6z\u0151 hat\u00f3anyagok fix kombin\u00e1ci\u00f3i. Az antihypertensiv\n                    ter\u00e1pia els\u0151 l\u00e9p\u00e9s\u00e9nek egy renin-angiotenzin-aldoszteron-rendszer-antagonist\u00e1nak\n                    (RAAS-g\u00e1tl\u00f3) a kalciumcsatorna-blokkol\u00f3kkal (CCB) vagy diuretikumokkal alkotott\n                    fix kombin\u00e1ci\u00f3it (FDC) javasolj\u00e1k. <jats:italic>C\u00e9lkit\u0171z\u00e9sek:<\/jats:italic> A szerz\u0151k\n                    c\u00e9lja a RAAS-g\u00e1tl\u00f3 FDC-k egy\u00e9ves perzisztenci\u00e1j\u00e1nak \u00f6sszehasonl\u00edt\u00e1sa volt\n                    hypertonia indik\u00e1ci\u00f3j\u00e1ban. <jats:italic>M\u00f3dszer:<\/jats:italic> Az Orsz\u00e1gos\n                    Eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si P\u00e9nzt\u00e1r v\u00e9nyforgalmi adataib\u00f3l azokat a betegeket\n                    v\u00e1lasztott\u00e1k ki a szerz\u0151k, akik a 2012. okt\u00f3ber 1. \u00e9s 2013. szeptember 30.\n                    k\u00f6z\u00f6tti id\u0151szakban els\u0151 alkalommal v\u00e1ltott\u00e1k ki b\u00e1rmely RAAS-g\u00e1tl\u00f3 FDC-k\n                    receptjeit, \u00e9s akik a bev\u00e1laszt\u00e1si id\u0151szakot megel\u0151z\u0151 egy \u00e9vben nem v\u00e1ltottak ki\n                    hasonl\u00f3 k\u00e9sz\u00edtm\u00e9nyeket. A perzisztencia modellez\u00e9s\u00e9re a t\u00fal\u00e9l\u00e9s-anal\u00edzis\n                    klasszikus eszk\u00f6zt\u00e1r\u00e1t alkalmazt\u00e1k, ahol a \u201et\u00fal\u00e9l\u00e9si\u201d id\u0151 a gy\u00f3gyszer szed\u00e9s\u00e9nek\n                    abbahagy\u00e1s\u00e1ig eltelt id\u0151 volt. <jats:italic>Eredm\u00e9nyek:<\/jats:italic> A bev\u00e1laszt\u00e1si\n                    k\u00f6vetelm\u00e9nyeknek 443\u00a0149 beteg felelt meg. Az angiotenzinkonvert\u00e1l\u00f3enzim-g\u00e1tl\u00f3\n                    (ACE-g\u00e1tl\u00f3)\/CCB FDC-k egy\u00e9ves perzisztenci\u00e1ja 44,59%, az\n                    angiotenzin-II-receptor-inhibitor (ARB)\/tiazid diuretikum (HCT) FDC-k eredm\u00e9nye\n                    42,52% volt, amelyet az ACE-g\u00e1tl\u00f3\/indapamid FDC-k 37,27%-kal, az ARB\/CCB FDC-k\n                    29,04%-kal, az ACE-g\u00e1tl\u00f3\/HCT FDC-k 27,47%-kal k\u00f6vettek. Az ACE-g\u00e1tl\u00f3\/indapamid\n                    FDC-hez (referencia) k\u00e9pest az ACE-g\u00e1tl\u00f3\/CCB-k elhagy\u00e1s\u00e1nak kock\u00e1zata\n                    31%-ponttal (HR = 0,69, 95% CI 0,6855\u20130,6996, p&lt;0,0001), az ARB\/HCT FDC-k\u00e9\n                    18%-ponttal (HR = 0,82, 95% CI 0,8096\u20130,8267, p&lt;0,0001) volt kedvez\u0151bb, m\u00edg\n                    az ACE-g\u00e1tl\u00f3\/HCT FDC-k\u00e9 17%-ponttal (HR = 1,17, 95% CI 1,1562\u20131,1825,\n                    p&lt;0,0001), az ARB\/CCB FDC-k\u00e9 20%-ponttal (HR = 1,20 95% CI 1,17316\u20131,2239,\n                    p&lt;0,0001) volt kedvez\u0151tlenebb. A 360 napra korl\u00e1tozott \u00e1tlagos\n                    gy\u00f3gyszerszed\u00e9si id\u0151 239,9 nap volt az ACE-g\u00e1tl\u00f3\/CCB FDC-k, 214,8 nap az ARB\/HCT\n                    FDC-k, 193,8 nap az ACE-g\u00e1tl\u00f3\/indapamid FDC-k, 178,8 nap az ARB\/CCB FDC-k \u00e9s\n                    177,6 nap az ACE-g\u00e1tl\u00f3\/HCT FDC-k eset\u00e9n. <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic> A\n                    szerz\u0151k hypertoni\u00e1s betegeken igazolt\u00e1k azt, hogy a RAAS-g\u00e1tl\u00f3 FDC-k egy\u00e9ves\n                    perzisztenci\u00e1ja jelent\u0151s m\u00e9rt\u00e9kben k\u00fcl\u00f6nb\u00f6zik. A legel\u0151ny\u00f6sebbnek az\n                    ACE-g\u00e1tl\u00f3\/CCB FDC-k bizonyultak. Orv Hetil. 2023; 164(34): 1337\u20131341.<\/jats:p>","DOI":"10.1556\/650.2023.32840","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:24:47Z","timestamp":1693293887000},"page":"1337-1341","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["Renin-angiotenzin-aldoszteron-rendszer-g\u00e1tl\u00f3k fix gy\u00f3gyszer-kombin\u00e1ci\u00f3inak egy\u00e9ves perzisztenci\u00e1ja hypertoni\u00e1s betegekben"],"prefix":"10.1556","volume":"164","author":[{"given":"G\u00e1bor","family":"Simonyi","sequence":"first","affiliation":[{"name":"D\u00e9l-budai Centrumk\u00f3rh\u00e1z, Szent Imre Egyetemi Oktat\u00f3k\u00f3rh\u00e1z, Anyagcsere K\u00f6zpont Budapest, T\u00e9t\u00e9nyi \u00fat 12\u201316., 1115 Magyarorsz\u00e1g"},{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, K\u00fcls\u0151 Obezitol\u00f3giai Tansz\u00e9k Budapest Magyarorsz\u00e1g"},{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, II. Belgy\u00f3gy\u00e1szati Klinika \u00e9s Nephrologiai, Diabetol\u00f3giai Centrum P\u00e9cs Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Ferenci","sequence":"additional","affiliation":[{"name":"\u00d3budai Egyetem, Neumann J\u00e1nos Informatikai Kar, \u00c9lettani Szab\u00e1lyoz\u00e1sok Csoport Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ervin","family":"Finta","sequence":"additional","affiliation":[{"name":"D\u00e9l-budai Centrumk\u00f3rh\u00e1z, Szent Imre Egyetemi Oktat\u00f3k\u00f3rh\u00e1z, Kiemelt Hotelszolg\u00e1lat I. Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mih\u00e1ly","family":"Medvegy","sequence":"additional","affiliation":[{"name":"Kistarcsai Fl\u00f3r Ferenc K\u00f3rh\u00e1z, III. Belgy\u00f3gy\u00e1szat-Kardiol\u00f3giai Oszt\u00e1ly Kistarcsa Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"Wittmann","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, II. Belgy\u00f3gy\u00e1szati Klinika \u00e9s Nephrologiai, Diabetol\u00f3giai Centrum P\u00e9cs Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","unstructured":"1 Hungarian Central Statistical Office. Hypertension. [K\u00f6zponti Statisztikai Hivatal. Magas v\u00e9rnyom\u00e1s.] Available from: https:\/\/www.ksh.hu\/ffi\/1-12.html [accessed: 25. 04. 2023]. [Hungarian]"},{"key":"ref1","unstructured":"2 Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 2021; 397: 1625-1636. Erratum: Lancet 2021; 397: 1884."},{"key":"ref2","unstructured":"3 Farsang C, J\u00e1rai Z, Nemcsik J, et al. The professional guidelines of the Hungarian Hypertension Society. [A Magyar Hypertonia T\u00e1rsas\u00e1g szakmai ir\u00e1nyelve.] Hyperton Nephrol. 2018; 22(6 klsz.): 1-48. [Hungarian]"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4 Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39: 3021-3104. Erratum: Eur Heart J. 2019; 40: 475.","DOI":"10.1093\/eurheartj\/ehy686"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11096-013-9891-8","article-title":"A method for calculating adherence to polypharmacy from dispensing data records","volume":"36","author":"5 Arnet","year":"2014","unstructured":"5 Arnet I, Abraham I, Messerli M, et al. A method for calculating adherence to polypharmacy from dispensing data records. Int J Clin Pharm. 2014; 36: 192-201.","journal-title":"Int J Clin Pharm"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6 Singer JD, Willett JB. Applied longitudinal data analysis: Modeling change and event occurrence. Oxford University Press, New York, NY, 2003.","DOI":"10.1093\/acprof:oso\/9780195152968.001.0001"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7 Mills M. Introducing survival and event history analysis. Sage Publications, London, 2011.","DOI":"10.4135\/9781446268360"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1037\/0022-006X.61.6.952","article-title":"Investigating onset, cessation, relapse, and recovery: why you should, and how you can, use discrete-time survival analysis to examine event occurrence","volume":"61","author":"Willett JB","year":"1993","unstructured":"8 Willett JB, Singer JD. Investigating onset, cessation, relapse, and recovery: why you should, and how you can, use discrete-time survival analysis to examine event occurrence. J Consult Clin Psychol. 1993; 61: 952-965.","journal-title":"J Consult Clin Psychol"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9 Simonyi G, Ferenci T, Finta E, et al. One-year persistence of fixed-dose combinations of angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertensive patients. [Az angiotenzinkonvert\u00e1l\u00f3enzim-g\u00e1tl\u00f3\/kalciumcsatorna-blokkol\u00f3 fix gy\u00f3gyszer-kombin\u00e1ci\u00f3k egy\u00e9ves perzisztenci\u00e1ja hypertoni\u00e1ban.] Orv Hetil. 2019; 160: 343-348. [Hungarian]","DOI":"10.1556\/650.2019.31355"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10 Simonyi G, Ferenci T. Medication adherence with the fixed combination of ramipril and amlodipine. [A ramipril\/amlodipin fix kombin\u00e1ci\u00f3 perzisztenci\u00e1ja.] Orv Hetil. 2014; 155: 1882-1888. [Hungarian]","DOI":"10.1556\/OH.2014.30037"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/0300060516645004","article-title":"Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence","volume":"44","author":"11 Simonyi","year":"2016","unstructured":"11 Simonyi G, Ferenci T, Alf\u00f6ldi S, et al. Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence. J Int Med Res. 2016; 44: 1087-1091.","journal-title":"J Int Med Res"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12 J\u00e1nosi A, Ferenci T, B\u00e1rsony G, et al. Practice of antiplatelet therapy in acute myocardial infarction. [A thrombocytaaggreg\u00e1ci\u00f3-g\u00e1tl\u00f3 kezel\u00e9s gyakorlata heveny sz\u00edvinfarktusban.] Orv Hetil. 2022; 163: 743-749. [Hungarian]","DOI":"10.1556\/650.2022.32453"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13 Papp-Zipernovszky O, Klinovszky A, Buz\u00e1s N. Illness knowledge of type 2 diabetes patients: the Hungarian validation of Diabetes Knowledge Test. [Betegs\u00e9gismeret 2-es t\u00edpus\u00fa diabetesszel \u00e9l\u0151k k\u00f6r\u00e9ben: a Diabetes Knowledge Test magyar nyelv\u0171 valid\u00e1l\u00e1sa.] Orv Hetil. 2021; 162: 870-877. [Hungarian]","DOI":"10.1556\/650.2021.32077"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/ajh\/hpab145","article-title":"Is medication adherence predictive of cardiovascular outcomes and blood pressure control? The systolic blood pressure intervention trial (SPRINT)","volume":"35","author":"14 Glasser","year":"2022","unstructured":"14 Glasser SP, Vitolins M, Rocco MV, et al. Is medication adherence predictive of cardiovascular outcomes and blood pressure control? The systolic blood pressure intervention trial (SPRINT). Am J Hypertens. 2022; 35: 182-191.","journal-title":"Am J Hypertens"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/34\/article-p1337.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/34\/article-p1337.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/34\/article-p1337.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T14:13:44Z","timestamp":1698329624000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/34\/article-p1337.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,27]]},"references-count":14,"journal-issue":{"issue":"34"},"URL":"https:\/\/doi.org\/10.1556\/650.2023.32840","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,27]]}}}